Wall Street analysts’ outlook for bioAffinity Technologies Inc. (BIAF)

bioAffinity Technologies Inc. (NASDAQ: BIAF) stock jumped 75.47% on Tuesday to $2.79 against a previous-day closing price of $1.59. With 68.61 million shares changed hands, the volume of the stock remained heavier than its average volume of 63600.0 shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $3.9900 whereas the lowest price it dropped to was $1.7000. The 52-week range on BIAF shows that it touched its highest point at $15.55 and its lowest point at $1.31 during that stretch.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BIAF was up-trending over the past week, with a rise of 73.29%, but this was up by 65.09% over a month.

Float and Shares Shorts:

At present, 8.37 million BIAF shares are outstanding with a float of 6.22 million shares on hand for trading. On Oct 13, 2022, short shares totaled 0.11 million, which was 3.86% higher than short shares on Sep 14, 2022. In addition to Ms. Maria Zannes J.D. as the firm’s Founder, Pres, CEO & Director, Dr. Vivienne I. Rebel M.D., Ph.D. serves as its Exec. VP and Chief Medical & Science Officer.


Institutional Ownership:

Through their ownership of 0.00% of BIAF’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 25.03% of BIAF, in contrast to — held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in BIAF with 0.35% of the stake, Creative Planning LLC holds 29,545 shares worth 29,545. A second-largest stockholder of BIAF, Citadel Securities LLC, holds 20,583 shares, controlling over 0.25% of the firm’s shares. Jane Street Capital LLC is the third largest shareholder in BIAF, holding 11,004 shares or 0.13% stake.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BIAF since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.. Analysts have provided yearly estimates in a range of -$1.94 being high and -$1.94 being low. For BIAF, this leads to a yearly average estimate of -$1.94. Based on analyst estimates, the high estimate for the next quarter is -$0.19 and the low estimate is -$0.19. The average estimate for the next quarter is thus -$0.19.

Summary of Insider Activity:

Insiders traded BIAF stock several times over the past three months with 4 Buys and 0 Sells. In these transactions, 32,576 shares were bought while 0 shares were sold. The number of buy transactions has increased to 35 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 1,498,370 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *